{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Prostate+Cancer&page=7", "query": { "condition": "Metastatic Prostate Cancer", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 1273, "total_pages": 128, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Prostate+Cancer&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Prostate+Cancer&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T00:59:33.035Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03442556", "title": "Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ATM Gene Mutation", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Castration Levels of Testosterone", "Castration-Resistant Prostate Carcinoma", "Homologous Recombination Deficiency", "Prostate Carcinoma Metastatic in the Bone", "PSA Level Greater Than or Equal to Two", "PSA Progression", "Stage IV Prostate Adenocarcinoma AJCC v7" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Rucaparib Camsylate", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 18, "start_date": "2018-08-24", "completion_date": "2025-06-04", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-24T00:59:33.035Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03442556" }, { "nct_id": "NCT02204072", "title": "BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [ { "name": "BI 836845", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 120, "start_date": "2014-11-11", "completion_date": "2023-06-01", "has_results": true, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-10-24T00:59:33.035Z", "location_count": 3, "location_summary": "Detroit, Michigan • New York, New York • Portland, Oregon", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02204072" }, { "nct_id": "NCT06991556", "title": "An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Hormone-sensitive Prostate Cancer" ], "interventions": [ { "name": "JSB462", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 168, "start_date": "2025-07-07", "completion_date": "2035-10-04", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-24T00:59:33.035Z", "location_count": 21, "location_summary": "La Jolla, California • Santa Monica, California • Denver, Colorado + 18 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06991556" }, { "nct_id": "NCT04109729", "title": "Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Radium-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 39, "start_date": "2020-09-16", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-24T00:59:33.035Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04109729" }, { "nct_id": "NCT04821622", "title": "Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "talazoparib plus enzalutamide", "type": "DRUG" }, { "name": "Placebo plus enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 599, "start_date": "2021-05-12", "completion_date": "2027-08-28", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-24T00:59:33.035Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04821622" }, { "nct_id": "NCT00134056", "title": "S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Cancer", "Prostate Cancer" ], "interventions": [ { "name": "atrasentan hydrochloride", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1038, "start_date": "2006-08", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2021-10-27", "last_synced_at": "2026-10-24T00:59:33.035Z", "location_count": 554, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 378 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00134056" }, { "nct_id": "NCT04550494", "title": "Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Castration-Resistant Prostate Carcinoma", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "HER2-Positive Breast Carcinoma", "Locally Advanced Breast Carcinoma", "Locally Advanced Gastric Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Ovarian Carcinoma", "Locally Advanced Pancreatic Carcinoma", "Locally Advanced Prostate Carcinoma", "Metastatic Breast Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Ovarian Carcinoma", "Metastatic Pancreatic Carcinoma", "Metastatic Prostate Carcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Prostate Carcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2021-04-26", "completion_date": "2027-07-27", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-24T00:59:33.035Z", "location_count": 4, "location_summary": "Gainesville, Florida • Bethesda, Maryland • Oklahoma City, Oklahoma", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04550494" }, { "nct_id": "NCT06520345", "title": "The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "177Lu-TLX591", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telix Pharmaceuticals (Innovations) Pty Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 520, "start_date": "2024-07-26", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-24T00:59:33.035Z", "location_count": 9, "location_summary": "Orange, California • Miami, Florida • Glen Burnie, Maryland + 6 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Glen Burnie", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06520345" }, { "nct_id": "NCT00003903", "title": "Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Osteoporosis", "Prostate Cancer" ], "interventions": [ { "name": "management of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 150, "start_date": "1999-07", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2013-10-16", "last_synced_at": "2026-10-24T00:59:33.035Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003903" }, { "nct_id": "NCT00433446", "title": "S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "CNTO 328", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 62, "start_date": "2007-04", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2013-02-05", "last_synced_at": "2026-10-24T00:59:33.035Z", "location_count": 123, "location_summary": "Anniston, Alabama • Springdale, Arkansas • Berkeley, California + 77 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00433446" } ] }